Oxford Biomedica PLC

Share Issue/Capital Change • Jul 25, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3332N

Oxford Biomedica PLC

25 July 2014

Block listing Application

Oxford, UK - 25 July 2014: Oxford BioMedica plc (LSE: OXB), ("OXB" or "the Company") a leading gene- and cell-therapy company, announces that applications have been made to the Financial Conduct Authority and the London Stock Exchange for admission to (i) the Premium segment of the Official List and (ii) to trading on the London Stock Exchange's markets for a block listing of securities totalling 15 million ordinary shares of 1 pence each (the "Ordinary Shares").

The Ordinary Shares are being reserved under a block listing and will be issued from time to time pursuant to the following schemes:

·     OXB Share Option Scheme (10 million Ordinary Shares); and

·     LTIP (5 million Ordinary Shares).

It is expected that admission of the Ordinary Shares will become effective on 28 July 2014. The Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares in issue.

-Ends-

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer	Tel: +44 (0)1865 783 000
Media Enquiries: Mary-Jane Elliott/Emma Thompson/Matthew Neal Consilium Strategic Communications	Tel: +44 (0)20 3709 5700

Notes for editors

About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy.  Through in-house and collaborative research, Oxford BioMedica has a broad range of partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCVELBLZDFZBBL